How does sample hemolysis interfere with clinical chemistry assays? Key Mechanisms & Susceptible Analytes

Hemolysis is one of the most common and insidious preanalytical errors, and its interference can instantly invalidate a clinical chemistry result. The core mechanism is simple: when red blood cells rupture, they dump their intracellular contents into the serum or plasma. This directly perturbs the concentration of analytes that exist at high levels inside RBCs, while the released hemoglobin itself can physically absorb light in colorimetric assays or chemically react with assay reagents, generating both false elevations and false depressions across a wide range of tests.

Hemolysis interferes through four primary routes: spectrophotometric absorption by free hemoglobin, dilution-independent release of intracellular constituents, chemical cross-reactivity with assay reagents, and enzymatic degradation of target molecules. This leads to falsely elevated potassium, LDH, AST, magnesium, and phosphate, while creating unreliable results for bilirubin, creatinine (Jaffe method), HbA1c, G6PD, and certain immunoassays—each through a distinct artifact mechanism.

The Mechanisms Behind Hemolysis Interference

The answer isn't just a list of analytes. To truly solve the problem, you need to understand the four biochemical and physical pathways that convert a ruptured red blood cell into an analytical disaster.

Spectrophotometric Interference: Hemoglobin’s Light-Absorbing Signature

Free hemoglobin is a potent chromophore. It absorbs light strongly at 415, 540, and 570 nm. Any colorimetric assay that reads at or near these wavelengths—such as many common endpoint or kinetic chemistries—will see a falsely high absorbance. This artificially elevates the reported concentration of the target analyte by adding an unaccounted-for optical signal.

This is not a concentration change in the analyte; it’s a pure optical artifact. Even a hemolysis level of 50 mg/dL (visible as a faint pink hue) can shift readings enough to move a result outside clinical decision limits. For bilirubin assays, this is particularly destructive, as the diazo reaction itself is read in a region where hemoglobin absorbs.

Dilution-Independent Release of Intracellular Components

Red blood cells contain dramatically higher concentrations of certain analytes than plasma. When they lyse, these analytes spill directly into the sample, and dilution is negligible at the specimen level. This mechanism causes a true chemical elevation, not just an optical one.

Key intracellular-rich analytes include:

• Potassium: Intracellular RBC potassium is ~25 times higher than plasma. Even a 1% hemolysis can raise serum potassium by 0.5 mmol/L, pushing a borderline result into the critical range.
• Lactate Dehydrogenase (LDH): RBC concentrations are roughly 150 times plasma levels. Hemolysis can more than double the measured LDH activity.
• Aspartate Aminotransferase (AST): Similarly enriched (40–50×), leading to proportional false elevations.
• Magnesium and Phosphate: Often overlooked, but both are concentrated inside RBCs and rise artifactually with hemolysis.
• Serum Folate: The primary reference highlights falsely elevated folate; indeed, RBC folate is the storage form, and release inflates serum measurements.

These elevations persist even if you use a blanking method to subtract the hemoglobin color, because you are measuring a chemically higher analyte mass.

Chemical Cross-Reactivity: When Hemoglobin Becomes a Reagent

Free hemoglobin is not just an inert pigment—it can act as a biocatalyst. Its pseudo-peroxidase activity, driven by the heme group, directly interferes with reactions that rely on peroxidase-linked detection systems.

In the classic Jendrassik-Gróf bilirubin assay, hemoglobin’s pseudo-peroxidase activity destroys the diazonium salt, inhibiting color formation and causing a falsely low bilirubin result. Similarly, in Jaffe-based creatinine assays, hemoglobin can generate a nonspecific chromogen, leading to a positive bias. This is one reason enzymatic creatinine methods have become preferred.

Another example is creatine kinase (CK) assays. Ruptured RBCs release adenylate kinase, which competes for ADP in the coupled enzyme reaction, producing an apparent CK activity that is not present. This elevates CK results independent of heart or muscle damage. And for some immunoassays, the heme group can quench chemiluminescent signals (as noted in the primary reference), artificially lowering the reported concentration of hormones, tumor markers, or therapeutic drugs.

Enzymatic Degradation of Target Analytes

Red blood cells also contain powerful proteases, such as cathepsin E, which are released upon lysis. These enzymes can cleave specific proteins within the sample, destroying epitopes recognized by immunoassay antibodies. The result is a falsely low signal—often misinterpreted as a genuinely decreased analyte level.

This mechanism is particularly dangerous for HbA1c assays. First, hemolysis introduces a higher proportion of younger, non-glycated RBCs, directly lowering the measured HbA1c percentage. Second, proteolytic digestion of the hemoglobin chains can further degrade the analyte, compounding the negative bias. A similar risk applies to protein-based immunoassays whose antibody clones are vulnerable to proteolysis, a critical consideration for assay developers selecting raw materials.

The Analytes Most Susceptible to Hemolysis Artifacts

Now we can map each analyte to its primary interference mechanism. The table below (conceptual) should guide you, but remember that many analytes suffer from more than one pathway.

Artifactually Elevated Analytes

• Potassium: Intracellular release. Visibly pink sample = discard.
• LDH: Massive intracellular release. Routinely flagged for rejection.
• AST: Intracellular release, less dramatic than LDH but clinically significant.
• Magnesium, Phosphate: Intracellular release, often underappreciated.
• Serum Folate: RBC folate release inflates serum levels.
• Creatinine (Jaffe): Nonspecific chromogen from hemoglobin creates positive bias.
• CK (creatine kinase): Adenylate kinase interference, not hemoglobin itself.

Artifactually Lowered Analytes

• Bilirubin (total and direct): Pseudo-peroxidase activity destroys diazonium salt, yielding false lows.
• HbA1c: Young RBC dilution effect and proteolytic degradation combine to lower the percentage.
• G6PD (glucose-6-phosphate dehydrogenase): Activity appears altered due to an imbalance of young vs. old RBCs; not a direct enzyme inhibition but a biological shift.
• Chemiluminescent immunoassays (e.g., troponin, TSH, hCG): Signal quenching by heme leads to false-negative or low results.

Analytes with Complex or Method-Dependent Artifacts

• Alkaline phosphatase (ALP): May be falsely elevated if the method uses a phosphate substrate, because hemolysis releases phosphate that can compete. Not always linear.
• Iron: Hemoglobin iron adds to serum iron, but the effect is often masked by concomitant binding proteins.

Understanding the Trade-offs and Hidden Risks

Even after recognizing these mechanisms, practical management reveals uncomfortable truths. Not all hemolysis is visible. A sample with 50 mg/dL free hemoglobin is clearly pink, but lower levels can still skew results for highly sensitive assays without any visual warning. Moreover, hemolysis is not a binary event—the degree of interference is often directly proportional to the hemoglobin concentration, requiring developers to establish thresholds experimentally.

Blank correction is not a universal fix. If you correct only for the optical absorbance of hemoglobin, you will not compensate for the chemical release of potassium or the enzymatic degradation of insulin. Each interference vector demands its own mitigation strategy.

Serum indices have limits. Modern chemistry analyzers measure hemolysis, icterus, and lipemia indices and can trigger automatic rejection. But these algorithms must be validated for each assay on that specific platform. A hemoglobin cutoff of 100 mg/dL may work for sodium but be completely unacceptable for LDH. Over-reliance on generic cutoffs leads to either rejecting too many valid specimens (reducing patient care efficacy) or accepting subtly corrupted results.

Finally, mitigation in reagent development is costly. As the supplementary references note, you can add adenylate kinase inhibitors to CK reagents, select protease-resistant antibody clones, or optimize detection wavelengths away from hemoglobin peaks. But each of these solutions increases raw material complexity, stability concerns, and manufacturing cost. They are necessary investments, but they must be justified by clinical risk-benefit analysis.

Making the Right Choice for Your Diagnostic Goal

Whether you are a laboratory director setting sample rejection criteria or an IVD manufacturer designing a new chemistry kit, your response to hemolysis must be surgical, not generic.

A brief introductory statement is followed by goal-specific actionable advice.

• If your primary focus is ensuring accurate patient results: Establish analyte-specific hemolysis cutoffs, never rely solely on visual inspection, and verify that your automated HIL indices align with each method’s actual interference profile.
• If your primary focus is developing robust IVD reagents: Screen antibody clones against proteolytically challenged matrices, incorporate adenylate kinase inhibitors into CK formulations, and select detection wavelengths that avoid the 415 nm, 540 nm, and 570 nm hemoglobin absorption zones.
• If your primary focus is minimizing sample rejection rates without compromising quality: Validate the lowest possible hemoglobin interference limit for clinically critical assays like potassium and LDH, while accepting slightly higher thresholds for less hemolysis-sensitive tests, and communicate clear preanalytical handling guidelines to collection sites.
• If your primary focus is forensic or research use with hemolyzed specimens: Employ targeted extraction methods to isolate clean nucleic acids, and use alternative protein precipitation steps to remove hemoglobin before immunoassay, always cross-referencing results with a non-hemolyzed baseline.

Hemolysis interference is not an unsolvable mystery. By mapping each active mechanism to the specific analyte vulnerability, you can move from blanket sample rejection to intelligent, assay-specific mitigation that preserves both data integrity and patient care efficiency.

Summary Table:

Build Interference-Resistant Assays with CamelBio

Overcoming matrix interference and preanalytical artifacts requires high-performance raw materials and robust formulation design. CamelBio provides diagnostic manufacturers, clinical labs, and research institutes with one-stop access to premium IVD raw materials, custom technical services, and expert consulting—covering every stage of your assay development from concept to clinic.

Whether you need enzyme inhibitors, protease-resistant antibody clones, or assay optimization support to mitigate hemolysis bias, our team is here to power your diagnostic accuracy.

Contact our IVD experts today to discuss your assay requirements!